TD9855
Showing 1 - 10 of 10
Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Pure Autonomic Failure Trial in
Completed
- Neurogenic Orthostatic Hypotension
- +7 more
- TD-9855
- Placebo
-
Long Beach, California
- +5 more
Aug 30, 2022
Attention-Deficit/Hyperactivity Disorder, ADHD Trial in United States (TD-9855, Placebo)
Completed
- Attention-Deficit/Hyperactivity Disorder
- ADHD
- TD-9855
- Placebo
-
Bradenton, Florida
- +16 more
Mar 24, 2022
Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy Trial (Ampreloxetine, Placebo)
Not yet recruiting
- Symptomatic Neurogenic Orthostatic Hypotension
- MSA - Multiple System Atrophy
- Ampreloxetine
- Placebo
- (no location specified)
Jan 13, 2023
Symptomatic Neurogenic Orthostatic Hypertension, nOH Trial in Miami, Orlando (Ampreloxetine)
Completed
- Symptomatic Neurogenic Orthostatic Hypertension
- nOH
-
Miami, Florida
- +1 more
Sep 7, 2021
Symptomatic Neurogenic Orthostatic Hypotension Trial in Worldwide (ampreloxetine)
Terminated
- Symptomatic Neurogenic Orthostatic Hypotension
-
Colorado Springs, Colorado
- +54 more
Nov 7, 2022
Symptomatic Neurogenic Orthostatic Hypotension, MSA, Parkinson's Disease (PD) Trial in Worldwide (ampreloxetine, Placebo)
Terminated
- Symptomatic Neurogenic Orthostatic Hypotension
- +3 more
- ampreloxetine
- Placebo
-
Sun City, Arizona
- +81 more
Dec 29, 2022
Symptomatic Neurogenic Orthostatic Hypotension Trial in Worldwide (ampreloxetine, Placebo)
Completed
- Symptomatic Neurogenic Orthostatic Hypotension
- ampreloxetine
- Placebo
-
Sun City, Arizona
- +124 more
Sep 15, 2021